At a glance
ClinicalIndex Comparison RecordPhase 2Active· 77 enrolled
Drug / intervention
Selpercatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
In Brief
A Phase 2 clinical trial evaluating Selpercatinib for Solid Tumor and Medullary Thyroid Cancer. Active but no longer recruiting, targeting 77 participants across 13 sites.
Detailed Summary
The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Medullary Thyroid Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Active
202020212022202320242025202620272028
First PostedFeb 2020
Enrollment StartMar 2020
Primary CompletionMar 2021
TodayJul 2026
Study CompletionNov 2027
First PostedFeb 21, 2020
Enrollment StartMar 16, 2020
Primary CompletionMar 25, 2021
Study CompletionNov 1, 2027
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 6.4 years ago
Interventions
Selpercatinibdrug
Administered orally